CD274 and non-small cell lung carcinoma: ICIs-based immune therapy has become the standard therapy for advanced and locally advanced NSCLC, regardless of immune status such as PD-L1 expression and TME characteristics, and has shown excellent efficacy when combined with chemotherapy49.